Oct. 18, 2009)
-- Safety Profiles of Disease-Modifying Anti-Rheumatic Drugs and Biologics
in Patients with Rheumatoid Arthritis: Observations from the RADIUS
Lead author: Gibofsky, A.
Abstract No. 1593 (Sunday, Oct. 18, 2009)
-- Identifying Clinical Features of Disseminated Histoplasmosis in
Patients Receiving TNF Inhibitors
Lead author: McCroskery, P.
Abstract No. 999 (Monday, Oct. 19, 2009)
Gary L. Stiles, M.D., executive vice president, Pfizer, added, "Amgen and Pfizer are committed to ongoing research of ENBREL to grow the overall amount of information available about ENBREL and its safety and efficacy profile."
ABOUT RHEUMATOID ARTHRITIS
According to the Arthritis Foundation, approximately 1.3 million Americans are affected by rheumatoid arthritis (RA), which can cause pain, stiffness, swelling and limitation in the motion and function of multiple joints. If RA is left untreated, joint damage caused by the disease can impair function, disabling some patients.
ENBREL is a soluble form of a fully human tumor necrosis factor (TNF) receptor and has 17 years of collective clinical experience with an established safety profile. ENBREL was first approved in 1998 for moderate to severe rheumatoid arthritis and was later approved to treat children and adolescents with juvenile rheumatoid arthritis (now called juvenile idiopathic arthritis) in 1999. ENBREL was approved in 2004 to treat moderate to severe plaque psoriasis in adults.
ENBREL indications in the U.S.:
Page: 1 2 3 4 5 6 7 8 9 Related medicine news :1
- ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
- ENBREL is indicated for reducing the signs and symptoms of moderately to severely activ
. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis2
. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Tuesday, October 273
. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Monday, October 264
. Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 255
. Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 246
. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 20097
. PolyOne Presented with Frost & Sullivan Medical Product Award8
. CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco9
. Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting10
. Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the Tipping Point in Treating Pressure Ulcers11
. CRF announces late breaking trials to be presented at TCT 2009 in San Francisco